WO2023097764A1 - 青蒿素在靶向抑制髓系来源的抑制性细胞及其在制备肿瘤免疫治疗药物中的应用 - Google Patents
青蒿素在靶向抑制髓系来源的抑制性细胞及其在制备肿瘤免疫治疗药物中的应用 Download PDFInfo
- Publication number
- WO2023097764A1 WO2023097764A1 PCT/CN2021/137750 CN2021137750W WO2023097764A1 WO 2023097764 A1 WO2023097764 A1 WO 2023097764A1 CN 2021137750 W CN2021137750 W CN 2021137750W WO 2023097764 A1 WO2023097764 A1 WO 2023097764A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- artemisinin
- myeloid
- tumor
- mdscs
- derived suppressor
- Prior art date
Links
- 210000004985 myeloid-derived suppressor cell Anatomy 0.000 title claims abstract description 91
- BLUAFEHZUWYNDE-NNWCWBAJSA-N artemisinin Chemical compound C([C@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2OC(=O)[C@@H]4C BLUAFEHZUWYNDE-NNWCWBAJSA-N 0.000 title claims abstract description 57
- 229960004191 artemisinin Drugs 0.000 title claims abstract description 57
- 229930101531 artemisinin Natural products 0.000 title claims abstract description 57
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 52
- 238000009169 immunotherapy Methods 0.000 title claims abstract description 25
- 239000003814 drug Substances 0.000 title claims abstract description 16
- 229940079593 drug Drugs 0.000 title claims abstract description 15
- 230000005764 inhibitory process Effects 0.000 title claims abstract description 10
- 238000002360 preparation method Methods 0.000 title claims abstract description 6
- 230000006907 apoptotic process Effects 0.000 claims abstract description 16
- 230000002776 aggregation Effects 0.000 claims abstract description 10
- 238000004220 aggregation Methods 0.000 claims abstract description 10
- 230000000259 anti-tumor effect Effects 0.000 claims abstract description 8
- 230000002401 inhibitory effect Effects 0.000 claims description 15
- 239000004480 active ingredient Substances 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 102000037982 Immune checkpoint proteins Human genes 0.000 claims description 4
- 108091008036 Immune checkpoint proteins Proteins 0.000 claims description 4
- 230000000903 blocking effect Effects 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 230000008685 targeting Effects 0.000 claims description 4
- 230000000694 effects Effects 0.000 abstract description 17
- 230000001506 immunosuppresive effect Effects 0.000 abstract description 7
- 238000011282 treatment Methods 0.000 abstract description 6
- 238000002474 experimental method Methods 0.000 abstract description 4
- 206010059866 Drug resistance Diseases 0.000 abstract description 3
- 230000008901 benefit Effects 0.000 abstract description 2
- 210000003162 effector t lymphocyte Anatomy 0.000 abstract description 2
- 230000002195 synergetic effect Effects 0.000 abstract description 2
- 231100000053 low toxicity Toxicity 0.000 abstract 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 30
- 210000004027 cell Anatomy 0.000 description 21
- 210000001744 T-lymphocyte Anatomy 0.000 description 17
- 230000014509 gene expression Effects 0.000 description 16
- 241000699670 Mus sp. Species 0.000 description 12
- 230000004614 tumor growth Effects 0.000 description 12
- 238000001514 detection method Methods 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- 238000000684 flow cytometry Methods 0.000 description 9
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 7
- 238000011740 C57BL/6 mouse Methods 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 210000000952 spleen Anatomy 0.000 description 6
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 5
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 238000001565 modulated differential scanning calorimetry Methods 0.000 description 5
- 102000004452 Arginase Human genes 0.000 description 4
- 102100021723 Arginase-1 Human genes 0.000 description 4
- 108700024123 Arginases Proteins 0.000 description 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
- 101000752037 Homo sapiens Arginase-1 Proteins 0.000 description 4
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 4
- 101000800287 Homo sapiens Tubulointerstitial nephritis antigen-like Proteins 0.000 description 4
- 102100022338 Integrin alpha-M Human genes 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 238000011529 RT qPCR Methods 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 3
- 210000004443 dendritic cell Anatomy 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 3
- 229960005277 gemcitabine Drugs 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 229930002330 retinoic acid Natural products 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 2
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 2
- 230000006820 DNA synthesis Effects 0.000 description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 2
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 2
- 102000011016 Type 5 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 description 2
- 108010037581 Type 5 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 229960002756 azacitidine Drugs 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 229960003668 docetaxel Drugs 0.000 description 2
- 229960002949 fluorouracil Drugs 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 210000003714 granulocyte Anatomy 0.000 description 2
- 230000002519 immonomodulatory effect Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- IOJUJUOXKXMJNF-UHFFFAOYSA-N 2-acetyloxybenzoic acid [3-(nitrooxymethyl)phenyl] ester Chemical compound CC(=O)OC1=CC=CC=C1C(=O)OC1=CC=CC(CO[N+]([O-])=O)=C1 IOJUJUOXKXMJNF-UHFFFAOYSA-N 0.000 description 1
- NMUSYJAQQFHJEW-UHFFFAOYSA-N 5-Azacytidine Natural products O=C1N=C(N)N=CN1C1C(O)C(O)C(CO)O1 NMUSYJAQQFHJEW-UHFFFAOYSA-N 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 102100035248 Alpha-(1,3)-fucosyltransferase 4 Human genes 0.000 description 1
- -1 Arg-1 Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 102100028989 C-X-C chemokine receptor type 2 Human genes 0.000 description 1
- 101100115215 Caenorhabditis elegans cul-2 gene Proteins 0.000 description 1
- 102100025621 Cytochrome b-245 heavy chain Human genes 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102000004594 DNA Polymerase I Human genes 0.000 description 1
- 108010017826 DNA Polymerase I Proteins 0.000 description 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102000006354 HLA-DR Antigens Human genes 0.000 description 1
- 108010058597 HLA-DR Antigens Proteins 0.000 description 1
- 101001022185 Homo sapiens Alpha-(1,3)-fucosyltransferase 4 Proteins 0.000 description 1
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108010018951 Interleukin-8B Receptors Proteins 0.000 description 1
- 239000002147 L01XE04 - Sunitinib Substances 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 101150109178 M1 gene Proteins 0.000 description 1
- 210000004322 M2 macrophage Anatomy 0.000 description 1
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 1
- 108010082739 NADPH Oxidase 2 Proteins 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 102000004495 STAT3 Transcription Factor Human genes 0.000 description 1
- 108010017324 STAT3 Transcription Factor Proteins 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 108010022394 Threonine synthase Proteins 0.000 description 1
- 102000005497 Thymidylate Synthase Human genes 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003817 anthracycline antibiotic agent Substances 0.000 description 1
- 230000000078 anti-malarial effect Effects 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 101150088826 arg1 gene Proteins 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000002573 chemokine receptor CXCR2 antagonist Substances 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 210000003690 classically activated macrophage Anatomy 0.000 description 1
- 238000011220 combination immunotherapy Methods 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000001335 demethylating effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000005965 immune activity Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000000066 myeloid cell Anatomy 0.000 description 1
- 210000003643 myeloid progenitor cell Anatomy 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 125000000864 peroxy group Chemical group O(O*)* 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000002718 pyrimidine nucleoside Substances 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229930009674 sesquiterpene lactone Natural products 0.000 description 1
- 150000002107 sesquiterpene lactone derivatives Chemical class 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 1
- 229960001796 sunitinib Drugs 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical class O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
- 235000005282 vitamin D3 Nutrition 0.000 description 1
- 239000011647 vitamin D3 Substances 0.000 description 1
- 229940021056 vitamin d3 Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
Definitions
- the invention belongs to the technical field of biomedicine, and in particular relates to the targeted inhibition of myeloid-derived suppressor cells by artemisinin and its application in the preparation of tumor immunotherapy drugs.
- Myeloid-derived suppressor cells in the tumor microenvironment are a group of heterogeneous cells derived from myeloid progenitor cells and immature myeloid cells, which are dendritic cells, macrophages and granulocytes. precursor. There are a large number of MDSCs expansion in the blood, spleen and tumor tissues of tumor-bearing mice and the peripheral blood and tumor tissues of tumor patients. Mouse MDSCs were defined as cells co-expressing Gr-1 and CD11b.
- mouse MDSCs can be divided into granulocyte-like MDSCs (G-MDSCs, CD11b + Ly6G + Ly6C low ) and monocyte-like MDSCs (M-MDSCs , CD11b + Ly6G - Ly6C high ) two subtypes.
- G-MDSCs granulocyte-like MDSCs
- M-MDSCs monocyte-like MDSCs
- the former are morphologically similar to polymorphonuclear granulocytes, while the latter have the morphology of monocytes.
- M-MDSCs mainly suppress T cell function in an antigen-nonspecific manner through high expression of arginase activity, while G-MDSCs use reactive oxygen species ROS as immune mediators to suppress T cell responses in an antigen-specific manner.
- the first type of therapeutic strategy is to induce the differentiation of MDSCs, such as sunitinib and all-trans retinoic acid (ATRA) or vitamin D3 They can differentiate MDSCs into more mature cells such as dendritic cells (DC) and stimulatory monocytes, showing antitumor efficacy, docetaxel (docetaxel , DTX) is an analogue of paclitaxel, mainly by inhibiting STAT3 phosphorylation of MDSCs and promote MDSCs differentiate to M1 to weaken Inhibition of MDSC; the second type of treatment strategy is to reduce the aggregation of MDSCs.
- ATRA all-trans retinoic acid
- DC dendritic cells
- DTX stimulatory monocytes
- gemcitabine is an antimetabolite of pyrimidine nucleoside analogs, which can inhibit nucleic acid reductase and DNA polymerase ⁇ , preventing DNA synthesis. Clinically, it is widely used in the treatment of pancreatic cancer, lung cancer, breast cancer and other tumors. In a variety of tumor animal models, GEM by reducing The number of MDSCs to resist tumor immunity.
- 5-fluorouracil 5-fluorouracil
- ADM an anthracycline antibiotic, and its metabolic active substance is embedded in a DNA base to form a complex, inhibiting DNA synthesis and transcription.
- ADM has been found to have immunomodulatory effects in a variety of tumor-bearing mouse models, and can selectively clear and inactivate MDSCs; chemokine receptor CXCR2 antagonists have been verified in multiple preclinical tumor models, by blocking YAP -1-CXCL5 inhibits the accumulation of MDSCs and may become an inhibitor of MDSCs accumulation; the third type of therapeutic strategy is to inhibit the immunosuppressive function of MDSCs, among which cyclooxygenase 2 (COX2) inhibitors, ROS inhibitors, and phosphodiesterase type 5 (PDE-5) inhibitors, nitroaspirin, and synthetic three mushroom compounds can inhibit MDSCs by reducing the expression of key proteins such as Arg-1, iNOS, or NOX2.
- Azacitidine (5-azacytidine , AZA) is a demethylating drug, in mice It can be observed in TC-1/A9 and TRAMP-C2 tumor models, can reduce MDSCs aggregation and inhibit MDSCs function.
- the above methods can only partially restore the effect of immunotherapy, and to further enhance the effect of immunotherapy, it is urgent to develop broad-spectrum, multi-target, less drug-resistant and safe and reliable MDSCs-targeted drugs to improve the effect of immunotherapy and increase the chance of clinical transformation. safety and efficacy.
- Artemisinin (Artemisinin, ART) and its derivatives are a class of sesquiterpene lactones containing peroxy groups. It was found that artemisinin and its derivatives not only have magical anti-malarial effects, but also have anti-tumor and immunomodulatory effects. Although current studies have tried to use artemisinin to treat tumor diseases, there is no study reporting artemisinin-targeted inhibition of myeloid-derived suppressor cell therapy and anti-PD-L1 antibody combination immunotherapy.
- the present invention aims to provide artemisinin in the targeted inhibition of myeloid-derived suppressor cells and its application in the preparation of tumor immunotherapy drugs.
- the first aspect of the present invention provides the application of artemisinin in the targeted inhibition of myeloid-derived suppressor cells.
- the artemisinin inhibits the aggregation of the myeloid-derived suppressor cells, promotes the apoptosis of the myeloid-derived suppressor cells, and suppresses their immune function.
- the artemisinin can polarize MDSCs from an M2-type tumor-promoting phenotype to an M1-type anti-tumor phenotype.
- the second aspect of the present invention provides a drug for targeting and inhibiting myeloid-derived suppressor cells, the active ingredient of which is artemisinin.
- the third aspect of the present invention provides the application of artemisinin in the preparation of tumor immunotherapy drugs.
- the fourth aspect of the present invention provides a pharmaceutical composition for tumor immunotherapy, the active ingredient of which includes artemisinin.
- the active ingredient of the pharmaceutical composition for tumor immunotherapy also includes an agent that blocks immune checkpoints.
- the agent for blocking immune checkpoints is an anti-PD-L1 antibody.
- the present invention proves through a large number of experiments that artemisinin can inhibit the aggregation of myeloid-derived inhibitory cells, promote the apoptosis of myeloid-derived inhibitory cells, target the inhibition of myeloid-derived inhibitory cells, and relieve the myeloid-derived inhibitory cells.
- the immunosuppressive effect of sex cells on effector T cells reverses the immunosuppressive state of the tumor microenvironment.
- Artemisinin is used as a suppressive cell drug targeting myeloid origin, and has the advantages of broad-spectrum efficacy, less toxic and side effects, unsuitable for drug resistance, and low cost. Artemisinin has an important application prospect in the field of tumor immunotherapy drugs, and can be used for combined immunotherapy for the treatment of tumors. Composition, combined application of artemisinin and anti-PD-L1 antibody immunotherapy to achieve synergistic anti-tumor effect.
- Figure 1 shows the effect of artemisinin on inhibiting the aggregation of MDSCs, promoting its apoptosis and releasing the inhibitory effect of MDSCs on T cells.
- Figures AB After three days of isolation and culture of MDSCs in vitro, different concentrations (50 ⁇ M, 100 ⁇ M, 300 ⁇ M, 500 ⁇ M) of artemisinin were added and DMSO was used as the control group to detect the apoptosis level and proportion of MDSCs by flow cytometry.
- FIG. 1 MDSCs were isolated and cultured in vitro for three days and then treated with 100 ⁇ M artemisinin for 12 hours, and then mixed with CD3 + T cells in the spleen at a ratio of 1:1, 1:2, 1:4, and 1:8. Each group was mixed and cultured for 3 days, and the proliferation of T cells was detected by flow cytometry.
- Figure 2 shows that artemisinin can polarize MDSCs from M2-type tumor-promoting phenotype to M1-type anti-tumor phenotype.
- Panels A-B Transcriptome sequencing results.
- Panel C qRT-PCR detection of the expression of M1 macrophage marker genes and M2 macrophage marker genes of MDSCs.
- Figure D Western blot detection of iNOS and ARG1 protein expression.
- Panel E Detection of intracellular arginase activity of MDSCs using a commercial kit.
- Panel F Nitric oxide levels measured by flow cytometry.
- Figure 3 shows that artemisinin can inhibit tumor growth in vivo and enhance anti-PD-L1 immunotherapy.
- Panels CF Mice were sacrificed on day 21 after tumor inoculation, and tumor tissues were collected for flow cytometric detection.
- the MDSCs isolated above were treated with 100 ⁇ M artemisinin for 12 hours, and the Gr-1 + cells were separated and purified by magnetic beads.
- Spleen of C57BL/6 mice was aseptically isolated, flow sorted and purified to obtain spleen CD3 + T cells, stained with 1 ⁇ M CFSE, and plated in 96-well plates at a cell concentration of 1 ⁇ 10 6 /ml.
- ConA (5ug/ml) stimulation, the background control group did not add ConA, each group set up 3 replicate wells.
- the purified MDSCs were added in the ratio of 1:1, 1:2, 1:4, 1:8 for mixed culture. Each group was mixed and cultured for 3 days, and the proliferation of T cells was detected by flow cytometry.
- Figure 1 shows the effect of artemisinin on inhibiting the aggregation of MDSCs, promoting its apoptosis and releasing the inhibitory effect of MDSCs on T cells.
- Figures AB After three days of isolation and culture of MDSCs in vitro, different concentrations (50 ⁇ M, 100 ⁇ M, 300 ⁇ M, 500 ⁇ M) of artemisinin were added and DMSO was used as the control group to detect the apoptosis level and proportion of MDSCs by flow cytometry.
- Figure 2 Artemisinin can polarize MDSCs from an M2-type tumor-promoting phenotype to an M1-type anti-tumor phenotype.
- Figures A-B Transcriptome sequencing showed that under the action of artemisinin, compared with the control group DMSO, the ARG1 immunosuppressive gene of MDSCs was down-regulated, and the expression of related genes in the M2 pathway was inhibited.
- Figure C qRT-PCR detection of the expression of M1-type macrophage marker genes and M2-type macrophage marker genes of MDSCs, the results show that compared with the control group DMSO, artemisinin can inhibit the expression of M2-type genes in MDSCs and up-regulate M1 type gene expression.
- Figure D Western blot detection of iNOS and ARG1 protein expression.
- Panel E Detection of intracellular arginase activity of MDSCs using a commercial kit.
- Panel F Nitric oxide levels measured by flow cytometry. The results showed that the content of arginine in MDSCs decreased and the content of nitric oxide increased under the action of artemisinin 100 ⁇ M. It shows that artemisinin can down-regulate the M2 type gene and protein expression of MDSCs, up-regulate M1 type, and make MDSCs polarize from M2 type to M1 type.
- Figure 3 Artemisinin is able to suppress tumor growth in vivo and enhance anti-PD-L1 immunotherapy.
- Fig. CF the mice were sacrificed on the 21st day after tumor inoculation, and the tumor tissues were taken for flow cytometric detection.
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
青蒿素在靶向抑制髓系来源的抑制性细胞及其在制备肿瘤免疫治疗药物中的应用。经过大量实验证明青蒿素可以抑制髓系来源的抑制性细胞的聚集，促进髓系来源的抑制性细胞的凋亡，靶向抑制髓系来源的抑制性细胞，解除髓系来源的抑制性细胞对效应T细胞的免疫抑制作用，逆转肿瘤微环境免疫抑制状态。青蒿素作为靶向髓系来源的抑制性细胞药物使用，具有广谱有效、毒副作用小、不宜耐药和成本经济等优势。青蒿素在肿瘤免疫治疗药物领域具有重要的应用前景，可以用于治疗肿瘤的联合免疫疗法，青蒿素和抗PD-L1抗体免疫疗法联合应用，实现协同增效的抗肿瘤效果。
Description
本发明属于生物医药技术领域，具体涉及青蒿素在靶向抑制髓系来源的抑制性细胞及其在制备肿瘤免疫治疗药物中的应用。
肿瘤微环境中髓系来源的抑制性细胞(myeloid-derived
suppressor cells， MDSCs）是一群异质性细胞，来源于骨髓祖细胞和未成熟髓细胞，是树突状细胞、巨噬细胞和粒细胞的前体。在荷瘤小鼠的血液、脾脏和肿瘤组织及肿瘤患者的外周血和肿瘤组织存在大量MDSCs的扩增。小鼠MDSCs
被定义为共表达Gr-1和CD11b的细胞。根据Gr-1的抗原表位Ly6G和Ly6C
两种分子表达的不同，小鼠MDSCs
可分为粒细胞样MDSCs
(G-MDSCs，CD11b
+Ly6G
+Ly6C
low
) 和单核细胞样MDSCs
(M-MDSCs，CD11b
+
Ly6G
-Ly6C
high ) 两种亚型。前者在形态学上与多形核粒细胞相似，后者则具有单核细胞的形态。人的MDSCs
还没有统一的表面标记可用于鉴定，目前的研究表明也存在不同表型的人类MDSCs亚型，其中包括CD14
+CD11b
+HLA-DR
low单核细胞样MDSCs和CD15
+粒细胞样MDSCs。M-MDSCs主要通过高表达精氨酸酶活性以抗原非特异性的方式抑制T细胞功能，而G-MDSCs则利用活性氧簇ROS作为免疫介质以抗原特异性地方式抑制T细胞反应。
基于MDSCs在肿瘤生长中发挥的作用，人们正在积极探索不同的治疗放法，目前治疗策略主要分为三种：第一类治疗策略是诱导MDSCs分化，如舒尼替尼和全反式维甲酸（ATRA）或维生素D3它们可以将MDSCs分化为例如树突状细胞（DC）和刺激性单核细胞等更成熟的细胞，显示出抗肿瘤疗效,多西他赛（docetaxel
，DTX）是紫杉醇的类似物，主要通过抑制
MDSCs的STAT3磷酸化和促使
MDSCs向M1分化来减弱
MDSC 的抑制作用；第二类治疗策略是减少MDSCs聚集，临床前以及临床实验表明低剂量吉西他滨和5-氟尿嘧啶均可以减少体内MDSCs的含量。吉西他滨（gemcitabine
，GEM）是一种嘧啶核苷类似物的抗代谢药，可以抑制核酸还原酶和DNA聚合酶α，阻止
DNA 的合成。临床上广泛用于胰腺癌、肺癌、乳腺癌等多种肿瘤的治疗。在多种肿瘤动物模型中，GEM通过降低
MDSCs的数量来抵抗肿瘤免疫。同样地，另一种抗代谢药5-氟尿嘧啶（5-Fu）小剂量应用时也能诱导MDSCs凋亡，而对T细胞、B细胞及NK细胞的数量没有明显影响，机制可能是MDSCs低表达胸苷酸合成酶。因此，GEM对MDSCs的作用主要表现为诱导凋亡。阿霉素（adriamycin，ADM
）是蒽环类抗生素，其代谢活性物嵌入DNA碱基中形成复合体，抑制
DNA 合成和转录。在多种荷瘤小鼠模型中发现ADM具有免疫调节效应，能选择性地清除和灭活MDSCs；趋化因子受体CXCR2拮抗剂已在多个临床前肿瘤模型中得到验证，通过阻断YAP-1-CXCL5抑制MDSCs积聚，可能成为MDSCs积聚的抑制剂；第三类治疗策略是抑制MDSCs免疫抑制功能，其中环氧化酶2（COX2）抑制剂、ROS抑制剂、5型磷酸二酯酶（PDE-5）抑制剂、硝基阿司匹林以及合成三菇类化合物均可以通过降低Arg-1、iNOS或NOX2等关键蛋白的表达起到抑制MDSCs的作用。阿扎胞苷（５-azacytidine
，AZA）是一种去甲基化药物，在小鼠
TC-１/A９和TRAMP‐C2肿瘤模型中可观察到，能减少MDSCs聚集和抑制MDSCs功能。
目前通过靶向MDSCs改善免疫治疗效果是该领域研究热点，但是已发表的相关研究中这些药物均具有靶点单一、容易产生耐药以及对机体毒副作用大等缺点。CXCR2 除表达于 MDSCs表面外，仍表达于成熟的中性粒细胞等；化疗药物引起MDSCs凋亡的同时诱导效应性细胞的凋亡；全反式维甲酸促进 MDSCs 向成熟细胞分化的同时诱导肿瘤相关的巨噬细胞和 Treg 细胞的产生。因此，上述手段只能部分恢复免疫治疗效果，进一步增强免疫治疗效应则迫切需要开发广谱性、多靶点、不易耐药和安全可靠的MDSCs靶向药物来改善免疫治疗效果，提高临床转化的安全性和有效性。
青蒿素(Artemisinin,ART)及其衍生物是一类含有过氧基团的倍半萜内酯类药物，现已成为国际社会上普遍认可并投入使用的抗疟疾首选药物，近年来，人们发现青蒿素及其衍生物不仅具有神奇的抗疟疾作用，而且具有抗肿瘤和免疫调节作用。虽然目前的研究已经试图开始尝试利用青蒿素来治疗肿瘤疾病，但目前尚无研究报道青蒿素靶向抑制髓系来源的抑制性细胞的疗法和抗PD-L1抗体组合的联合免疫疗法。
为了解决现有技术中的不足，本发明旨在提供青蒿素在靶向抑制髓系来源的抑制性细胞及其在制备肿瘤免疫治疗药物中的应用。
本发明第一方面提供青蒿素在靶向抑制髓系来源的抑制性细胞中的应用。
进一步地，所述青蒿素抑制髓系来源的抑制性细胞的聚集，促进髓系来源的抑制性细胞的凋亡，抑制其免疫功能。
进一步地，所述青蒿素能够使MDSCs从M2型促肿瘤表型向M1型抗肿瘤表型极化。
本发明第二方面提供一种靶向抑制髓系来源的抑制性细胞的药剂，其活性成分为青蒿素。
本发明第三方面提供青蒿素在制备肿瘤免疫治疗药物中的应用。
本发明第四方面提供一种肿瘤免疫治疗药物组合物，其活性成分包括青蒿素。
进一步地，所述的肿瘤免疫治疗药物组合物，其活性成分还包括阻断免疫检查点的药剂。
优选地，所述阻断免疫检查点的药剂为抗PD-L1抗体。
本发明的有益效果为：
本发明经过大量实验证明青蒿素可以抑制髓系来源的抑制性细胞的聚集，促进髓系来源的抑制性细胞的凋亡，靶向抑制髓系来源的抑制性细胞，解除髓系来源的抑制性细胞对效应T细胞的免疫抑制作用，逆转肿瘤微环境免疫抑制状态。青蒿素作为靶向髓系来源的抑制性细胞药物使用，具有广谱有效、毒副作用小、不宜耐药和成本经济等优势。青蒿素在肿瘤免疫治疗药物领域具有重要的应用前景，可以用于治疗肿瘤的联合免疫疗法，该联合免疫疗法由靶向抑制髓系来源的抑制性细胞的疗法和抗PD-L1抗体免疫疗法组成，青蒿素和抗PD-L1抗体免疫疗法联合应用，实现协同增效的抗肿瘤效果。
图1为青蒿素作用下抑制MDSCs的聚集，促进其凋亡及解除MDSCs对T细胞抑制作用的影响。图A-B：体外分离培养MDSCs三天后加入不同浓度（50μM、100μM、300μM、500μM）青蒿素以DMSO为对照组流式检测MDSCs的凋亡水平和比例变化。图C：体外分离培养MDSCs三天后加入100μM青蒿素处理12小时，与脾脏中CD3
+
T细胞以1:1、1:2、1：4、1：8
的比例加入其中混合培养。各组混合培养3天，流式细胞术检测T细胞增殖情况。
图2为青蒿素能够使MDSCs从M2型促肿瘤表型向M1型抗肿瘤表型极化。图A-B：转录组测序结果。图C：qRT- PCR 检测MDSCs的M1型巨噬细胞标志基因和M2型巨噬细胞标志基因的表达。图D：Western blot检测iNOS和ARG1蛋白表达。图E：利用商品化试剂盒检测MDSCs细胞内精氨酸酶活性。图F：流式检测一氧化氮水平。
图3为青蒿素能够在体内抑制肿瘤生长，并提高抗PD-L1免疫疗法。图A-B：取6-8
周大小SPF级C57BL/6小鼠，皮下接种s.c. 1×10
6 B16F10细胞或1×10
7 Hepa1-6细胞，待肿瘤长出后给予对照组（DMSO）处理、青蒿素药物（50mg/kg）处理，在肿瘤长出后第一周每隔一天给予anti-PD-L1（10mg/kg），连续观察3周小鼠肿瘤生长情况，每天记录小鼠肿瘤长直径和短直径，按照公式肿瘤体积（mm
3）=长直径×短直径
2×1/2统计小鼠肿瘤体积变化。图C-F：于肿瘤接种后第21天处死小鼠取肿瘤组织进行流式检测。
为了更清楚地理解本发明，现参照下列实施例及附图进一步描述本发明。实施例仅用于解释而不以任何方式限制本发明。实施例中，各原始试剂材料均可商购获得，未注明具体条件的实验方法为所属领域熟知的常规方法和常规条件，或按照仪器制造商所建议的条件。
实施例1
（1）体外检测青蒿素处理对MDSCs聚集和凋亡的影响
新鲜分离的C57BL/6小鼠的骨髓细胞，用含10% FBS 的RPMI 1640 培养基将细胞密度调整至1×10
6/ml，依此加入40ng/ml GM-CSF 和40ng/ml IL-6。充分混匀后，将细胞混合液铺板于24孔板中，培养于37℃、5%
CO
2培养箱中。在培养至第三天时加入ART （50μM、100μM、300μM、500μM），以DMSO为对照组流式检测MDSCs比例和凋亡。
（2）体外检测青蒿素处理对解除MDSCs对T细胞的抑制作用的影响
取上述分离的MDSCs加入100μM青蒿素处理12小时，并用磁珠分离纯化Gr-1
+细胞。无菌分离C57BL/6小鼠脾脏，流式分选纯化得到其脾脏CD3
+ T细胞、并以1μM CFSE 对其染色，以1×10
6 /ml 细胞浓度铺板于96 孔板中，实验组加ConA (5ug/ml)刺激，本底对照组不加ConA，每组设3个复孔。再将纯化的MDSCs 以1:1、1:2、1：4、1：8 的比例加入其中混合培养。各组混合培养3天，流式细胞术检测T细胞增殖情况。
图1为青蒿素作用下抑制MDSCs的聚集，促进其凋亡及解除MDSCs对T细胞抑制作用的影响。图A-B：体外分离培养MDSCs三天后加入不同浓度（50μM、100μM、300μM、500μM）青蒿素以DMSO为对照组流式检测MDSCs的凋亡水平和比例变化。结果显示与DMSO相比，随着青蒿素浓度越高MDSCs的凋亡水平逐渐增加，MDSCs比例越来越低，说明青蒿素可以在体外促进MDSCs凋亡并抑制MDSCs聚集，且成浓度依赖性。图C：体外分离培养MDSCs三天后加入100μM青蒿素处理12小时，与脾脏中CD3
+ T细胞以1:1、1:2、1：4、1：8 的比例加入其中混合培养。各组混合培养3天，流式细胞术检测T细胞增殖情况。结果显示，青蒿素处理后的MDSCs细胞与对照组DMSO相比，T细胞的增殖水平明显升高，说明青蒿素处理的MDSCs解除了对T细胞的抑制作用。
实施例2
通过转录组测序结果分析显示，青蒿素作用下与对照组DMSO相比，MDSCs抑制M2型通路相关基因的表达。并用Western Blot 和qRT- PCR 检测MDSCs 细胞内免疫抑制因子基因ARG1、M1型基因iNOS的表达，利用商品化试剂盒检测MDSCs细胞内精氨酸酶和一氧化氮水平。
图2：青蒿素能够使MDSCs从M2型促肿瘤表型向M1型抗肿瘤表型极化。
图A-B：转录组测序显示，青蒿素作用下与对照组DMSO相比，MDSCs的ARG1免疫抑制基因下调，且抑制M2型通路的相关基因表达。图C：qRT- PCR 检测MDSCs的M1型巨噬细胞标志基因和M2型巨噬细胞标志基因的表达，结果显示与对照组DMSO相比，青蒿素可以抑制MDSCs的M2型基因表达并上调M1型基因的表达。图D：Western blot检测iNOS和ARG1蛋白表达。结果显示在我们选用的100μM浓度时iNOS表达升高而ARG1表达降低。图E：利用商品化试剂盒检测MDSCs细胞内精氨酸酶活性。图F：流式检测一氧化氮水平。结果显示在青蒿素100μM的作用下MDSCs精氨酸含量降低而一氧化氮含量增加。说明青蒿素能够下调MDSCs的M2型基因和蛋白表达，上调M1型，使MDSCs从M2型向M1型极化。
实施例3
在C57BL/6小鼠体内分别建立B16F10、Hepa1-6两种肿瘤模型，验证体内青蒿素抑制肿瘤生长的效果，并与anti-PD-L1抗体联用增强anti-PD-L1免疫疗法。
取6-8 周大小SPF级C57BL/6小鼠，皮下接种s.c. 1×10
6
B16F10细胞或1×10
7
Hepa1-6细胞，待肿瘤长出后给予对照组（DMSO）处理、青蒿素药物（50mg/kg）处理，在肿瘤长出后第一周每隔一天给予anti-PD-L1（10mg/kg），每天记录小鼠肿瘤长直径和短直径，按照公式肿瘤体积（mm
3）=长直径×短直径
2×1/2统计小鼠肿瘤体积变化，于肿瘤接种后第21天，取小鼠骨髓、脾脏以及肿瘤组织进行流式检测。
图3：青蒿素能够在体内抑制肿瘤生长，并提高抗PD-L1免疫疗法。
图A-B：取6-8
周大小SPF级C57BL/6小鼠，皮下接种s.c. 1×10
6 B16F10细胞或1×10
7 Hepa1-6细胞，待肿瘤长出后给予对照组（DMSO）处理、青蒿素药物（50mg/kg）处理，在肿瘤长出后第一周每隔一天给予anti-PD-L1（10mg/kg），连续观察3周小鼠肿瘤生长情况，每天记录小鼠肿瘤长直径和短直径，按照公式肿瘤体积（mm
3）=长直径×短直径
2×1/2统计小鼠肿瘤体积变化。图C-F于肿瘤接种后第21天处死小鼠取肿瘤组织进行流式检测。结果显示与对照组DMSO相比，青蒿素和anti-PD-L1单独作用时均可抑制肿瘤生长，联用后效果更佳。在肿瘤组织中流式结果显示，青蒿素可以抑制肿瘤组织中MDSCs及其亚群的比例，增强CD3
+ T细胞、CD4
+ T细胞的比例，青蒿素与anti-PD-L1联用后可以提高anti-PD-L1对MDSCs及其亚群的抑制作用以及提高anti-PD-L1对CCD3
+ T细胞、CD4
+ T细胞免疫活力。说明青蒿素能够在体内抑制肿瘤生长，与抗PD-L1抗体联用后可以提高抗PD-L1免疫疗法。
显然，上述实施例仅仅是为清楚地说明所作的举例，而并非对实施方式的限定。对于所属领域的普通技术人员来说，在上述说明的基础上还可以做出其它不同形式的变化或变动。这里无需也无法对所有的实施方式予以穷举。而由此所引伸出的显而易见的变化或变动仍处于本发明创造的保护范围之中。
Claims (8)
- 青蒿素在靶向抑制髓系来源的抑制性细胞中的应用。
- 根据权利要求1所述的应用，其特征在于，所述青蒿素抑制髓系来源的抑制性细胞的聚集，促进髓系来源的抑制性细胞的凋亡。
- 根据权利要求1所述的应用，其特征在于，所述青蒿素使髓系来源的抑制性细胞从M2型促肿瘤表型向M1型抗肿瘤表型极化。
- 一种靶向抑制髓系来源的抑制性细胞的药剂，其特征在于，其活性成分为青蒿素。
- 青蒿素在制备肿瘤免疫治疗药物中的应用。
- 一种肿瘤免疫治疗药物组合物，其特征在于，其活性成分包括青蒿素。
- 根据权利要求6所述的肿瘤免疫治疗药物组合物，其特征在于，所述活性成分还包括阻断免疫检查点的药剂。
- 根据权利要求7所述的肿瘤免疫治疗药物组合物，其特征在于，所述阻断免疫检查点的药剂为抗PD-L1抗体。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111458936.5 | 2021-12-01 | ||
| CN202111458936.5A CN114191430A (zh) | 2021-12-01 | 2021-12-01 | 青蒿素在靶向抑制髓系来源的抑制性细胞及其在制备肿瘤免疫治疗药物中的应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2023097764A1 true WO2023097764A1 (zh) | 2023-06-08 |
Family
ID=80650163
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/CN2021/137750 WO2023097764A1 (zh) | 2021-12-01 | 2021-12-14 | 青蒿素在靶向抑制髓系来源的抑制性细胞及其在制备肿瘤免疫治疗药物中的应用 |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN114191430A (zh) |
| WO (1) | WO2023097764A1 (zh) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112773788A (zh) * | 2020-09-29 | 2021-05-11 | 上海市肺科医院 | 双氢青蒿素在制备非小细胞肺癌药物中的应用 |
| CN112891339A (zh) * | 2021-01-27 | 2021-06-04 | 中国药科大学 | 包封青蒿素的血红素纳米囊泡、制备方法和用途 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113304146A (zh) * | 2021-06-05 | 2021-08-27 | 澳门大学 | 双氢青蒿素类化合物在制备pd-l1表达抑制剂中的应用 |
-
2021
- 2021-12-01 CN CN202111458936.5A patent/CN114191430A/zh active Pending
- 2021-12-14 WO PCT/CN2021/137750 patent/WO2023097764A1/zh unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112773788A (zh) * | 2020-09-29 | 2021-05-11 | 上海市肺科医院 | 双氢青蒿素在制备非小细胞肺癌药物中的应用 |
| CN112891339A (zh) * | 2021-01-27 | 2021-06-04 | 中国药科大学 | 包封青蒿素的血红素纳米囊泡、制备方法和用途 |
Non-Patent Citations (5)
| Title |
|---|
| CAO YU; FENG YONG-HUI; GAO LI-WEI; LI XIAO-YING; JIN QUAN-XIU; WANG YU-YING; XU YING-YING; JIN FENG; LU SHI-LONG; WEI MIN-JIE: "Artemisinin enhances the anti-tumor immune response in 4T1 breast cancer cellsin vitroandin vivo", INTERNATIONAL IMMUNOPHARMACOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 70, 1 January 1900 (1900-01-01), NL , pages 110 - 116, XP085646120, ISSN: 1567-5769, DOI: 10.1016/j.intimp.2019.01.041 * |
| LI LING, ZHE WANG, NING-HUA TAN: "Advances in natural products that target the tumor microenvironment", ACTA PHARMACEUTICA SINICA, vol. 56, no. 6, 14 April 2021 (2021-04-14), pages 1580 - 1590, XP093068708, DOI: 10.16438/j.0513-4870.2021-0010 * |
| LI, DAN ET AL.: "Protective effect of dihydroartemisinin in inhibiting senescence of myeloid-derived suppressor cells from lupus mice via Nrf2/HO-1 pathway", FREE RADICAL BIOLOGY AND MEDICINE, vol. 143, no. 1 supplement, 13 August 2019 (2019-08-13), pages 260 - 274, XP085901679, DOI: 10.1016/j.freeradbiomed.2019.08.013 * |
| WANQING CHEN, ZHANG BO，CAO YAJUAN，LUI YINGBIN，LI YAN: "Research Progress on Myeloid-derived Suppressor Cells Mediating Tumor Immune Microenvironment Remodeling and Targeted Therapy", SHANGHAI JOURNAL OF TRADITIONAL CHINESE MEDICINE, vol. 53, no. 11, 30 November 2019 (2019-11-30), pages 92 - 97, XP093068706 * |
| YAN DEHONG, ZHANG MENGQI, ADESHAKIN ADELEYE O, WAN XIAOCHUN, METRICS INFO &, , : "Artemisinin improves the efficiency of anti-PD-L1 therapy in T-cell lymphoma", vol. 204, no. Suppl 1, 1 May 2020 (2020-05-01), pages 241.46, XP093068686 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114191430A (zh) | 2022-03-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20220401465A1 (en) | Uses of nad+ and/or nad+ inhibitors and/or nad+ agonists and combination preparation thereof | |
| CN115957306B (zh) | 一种Caerin1.1/1.9联合抗CD47抗体在制备治疗黑色素瘤药物中的应用 | |
| WO2020028686A1 (en) | Targeting piezo1 for treatment of cancer and infectious diseases | |
| Crezee et al. | Metabolic programming of tumor associated macrophages in the context of cancer treatment | |
| CN105233292A (zh) | Ory-1001联合放疗和化疗用于治疗人三阴性乳腺癌的用途 | |
| Xiao et al. | Dihydroartemisinin inhibits Lewis Lung carcinoma progression by inducing macrophages M1 polarization via AKT/mTOR pathway | |
| Shen et al. | Low-dose salinomycin inhibits breast cancer metastasis by repolarizing tumor hijacked macrophages toward the M1 phenotype | |
| Hwang et al. | Oridonin enhances cytotoxic activity of natural killer cells against lung cancer | |
| EP3733212A1 (en) | Pharmaceutical composition for preventing or treating cancer metastasis to lung, containing chi3l1 inhibitor as active ingredient | |
| EP4427753A1 (en) | Immunomodulator composition comprising azvudine | |
| EP3682889B1 (en) | Modulating inflammasome activation of myeloid-derived suppressor cells for treating gvhd | |
| Glenn et al. | Gemcitabine directly inhibits effector CD4 T cell activation and prevents experimental autoimmune encephalomyelitis | |
| TWI606835B (zh) | 基於靈芝多醣之組合物及治療癌症之方法 | |
| WO2023097764A1 (zh) | 青蒿素在靶向抑制髓系来源的抑制性细胞及其在制备肿瘤免疫治疗药物中的应用 | |
| CN115634287A (zh) | 一种基于砷化合物的肿瘤疫苗及其制备方法和应用 | |
| CN114917359A (zh) | 针对细胞周期多时空分布抗癌靶点的protac组合物 | |
| Zyuz’kov et al. | Antitumor effects of JAK3 inhibitor on the model of transplantable lewis lung carcinoma and mechanisms of their development | |
| CN109985030B (zh) | 醌式查尔酮化合物在制备抗肿瘤药物中的应用 | |
| CN110812384A (zh) | 一种甘草中有效成分及其衍生物的医药新用途 | |
| Zhang et al. | Rhein exerts anti-multidrug resistance in acute myeloid leukemia via targeting FTO to inhibit AKT/mTOR | |
| CN112516298B (zh) | 一种靶向EpCAM-CART细胞与hsBCL9CT-24的组合在抗肿瘤中的应用 | |
| CN116617222B (zh) | 小分子离子通道阻滞剂mk-801在制备治疗肿瘤或抗感染药物的应用 | |
| CN114042158B (zh) | Cxcl5抑制剂在制备治疗肿瘤的药物中的应用 | |
| Reynolds | Ph. D. Surgery and Philosophy March 2022 | |
| URZÌ et al. | LEMON-DERIVED EXTRACELLULAR VESICLES EXERT ANTI-INFLAMMATORY EFFECTS BY INHIBITING THE ERK/NF-KB PATHWAY. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21966188 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |